AIDS encephalopathy with response to treatment

J MATTHES,* L A WALKER,† J G WATSON,* AND A G BIRD†

 Departments of *Paediatrics and †Immunology, Newcastle General Hospital, Newcastle upon Tyne

SUMMARY A 3 year old boy who had acquired HIV infection transplacentally developed the classical features of AIDS encephalopathy, spastic diplegia and expressive aphasia. His computed tomogram showed cerebral atrophy. Treatment with zidovudine and weekly infusions of gammaglobulin led to considerable clinical improvement and an almost normal computed tomogram nine weeks later.

A boy was identified as HIV antibody positive at the age of 21 months after his mother presented and died of pneumonia due to Pneumocystis carinii. She was HIV antibody positive and had received two units of blood after the birth of her first child. The source of her infection remains unclear. The first child is well at age 6 and has no detectable HIV antibody. Our patient, the second child, is thought to have acquired HIV transplacentally.

The boy was born after a full term normal delivery, birth weight 3150 g, and he received all conventional immunisations, including measles, without problem. His head circumference, weight, and length had grown along the 50th, 10th, and 10th centiles, respectively. His development was normal, and he had been walking normally since age 13 months and, aged 21 months, was starting to join words. The only clinical abnormality was moderate inguinal lymphadenopathy.

Initial investigation showed normal T lymphocyte subsets (fig 1) and a normal number of T helper cells. He had a grossly raised IgG (37 g/l) concentration but no IgG virus antibodies (including measles

References


Correspondence to Dr EH Price, Department of Microbiology, Queen Elizabeth Hospital for Children, Hackney Road, London E2 8PS.

Accepted 10 February 1988
and polio) were detected; this suggested impaired production of functional antibody. IgM isoahemagglutinins were present. Delayed type hypersensitivity skin tests with passive phytohaemagglutinin gave normal results.

At the age of 22 months he developed pertussis that was proved on culture. Despite early treatment from day seven of the illness with erythromycin, Bordetella pertussis could still be isolated at 28 days. Age 25 months he developed unilateral submandibular lymphadenitis with Streptococcus pyogenes cultured from the fauces. This responded rapidly to drainage (culture negative) and intravenous benzylpenicillin. His T4 cells were now depleted (fig 1) and IgG concentrations were diminished. One month later he developed a right lower lobe pneumonia with a heavy growth of Haemophilus influenzae from pharyngeal secretions. Despite physiotherapy and appropriate antibiotics there was little clinical response but high dose intravenous cotrimoxazole gave rapid resolution.

Over two weeks during this illness his speech rapidly regressed to expressive aphasia with only vowel sounds but with no cognitive impairment. He also rapidly developed a considerable spastic diplegia with inability to walk. A computed tomogram showed cerebral atrophy (fig 2). Sensory and motor nerve conduction studies gave normal results. His cerebrospinal fluid showed no white cells and normal concentrations of glucose and protein. No bacteria, fungi, or viruses were cultured. IgG antibodies to HIV were selectively increased in the cerebrospinal fluid. The antibody to albumin ratio given by the equation

\[
\frac{[\text{HIV in cerebrospinal fluid} - \text{IgG}]}{[\text{Serum albumin}]}
= \frac{[\text{Serum HIV} - \text{IgG}]}{[\text{Albumin in cerebrospinal fluid}]}
\]

was 110 (upper limit of normal is 2), indicating production of HIV antibody in the cerebrospinal fluid, and is evidence of HIV infection within the nervous system.

The patient was treated with intravenous gammaglobulin 300 mg/kg. He was initially treated weekly because his IgG concentration was 14.2 g/l; he was also given oral zidovudine (Retrovir) 100 mg/m² four times a day, equivalent to 16 mg/kg/day. This thymidine analogue selectively inhibits DNA chain elongation of the HIV but does not eradicate the viral genome from infected cells. Treatment with zidovudine and intravenous gammaglobulin every four weeks has continued for eight months. The intravenous preparation of zidovudine was given orally without acceptance problems and we have seen no haematological or neurological toxicity. A plasma profile of zidovudine showed a peak of 2-9 μM of active drug with 10-9 μM of glucuronide metabolite one hour after ingestion.

The boy has been cared for at home by his father and his general well being has remained good over eight months. He is now gaining weight normally. Spasticity has regressed allowing him to run unaided across the room, and his reflexes are now normal. He can articulate several single words. A repeat computed tomogram after nine weeks treatment showed considerable improvement (fig 3). His
AIDS encephalopathy with response to treatment 547

French group reported eight children with HIV encephalopathy of whom two became normal, three had a partial improvement, and three no real improvement (S Blanche. Abstract presented at the Wellcome International Antiviral Symposium, as above). These early results compare with the American experience of administering doses two to three times as great by continuous intravenous infusion. This was associated with noticeable improvement in all encephalopathic children, but unfortunately also with a high incidence of catheter related infections (PA Pizzo. Abstracts presented at the Wellcome International Antiviral Symposium, as above).

The immunological improvement could, however, be attributed in part to intravenous gammaglobulin. The fall in T4 numbers 12 weeks after starting zidovudine is consistent with recent reports. At this dose of zidovudine we saw no toxic effects with haematological indices, liver and kidney function remaining normal. Marrow suppression during zidovudine treatment, however, is as common in children as in adults.

Zidovudine is an expensive drug in limited supply. As the dose depends on weight, more children than adults can be treated for the same cost. We believe this case should encourage others to use zidovudine in children with AIDS encephalopathy. Further studies will be required to determine the optimum dose, whether combination treatment of zidovudine plus acyclovir or gammaglobulin confers benefit, for how long treatment should continue, and whether neurological improvement is maintained.

We are grateful to Dr Yap and the Scottish National Blood Transfusion Service for the supply of gammaglobulin and to the Wellcome Foundation Ltd for supplies of Retrovir solution.

Discussion

AIDS encephalopathy in childhood usually presents with language deficits, developmental regression, pyramidal signs, and cortical atrophy. The encephalopathy may be static or progressive and, untreated, is associated with a very bad prognosis. Data have only recently become available that suggest that children with HIV encephalopathy may improve when treated with zidovudine with or without intravenous gammaglobulin (S Blanche and PA Pizzo. Abstracts presented at the Wellcome International Antiviral Symposium, Monte Carlo, 2–4 December 1987). There are reports of neurological improvement in adults treated with zidovudine.

The response to zidovudine may be dose dependent. Using 100 mg/m² intravenously for two weeks followed by 100 mg/m² orally four times a day, a lymphocyte subsets initially became more normal but T4 concentrations fell 12 weeks after starting zidovudine (fig 1). These have now returned to normal (not shown in figure).

References


Correspondence to Dr JG Watson, Department of Paediatrics, Newcastle General Hospital, Westgate Road, Newcastle upon Tyne NE4 6BE

Accepted 30 December 1987